The first trial that tested a GLP-1 in a population with a mood disorder was published in January 2026 by Badulescu et al in Canada, to see if semaglutide (Ozempic) was a viable treatment of cognitive dysfunction in major depressive disorder (MDD), using 72 participants over the course of 16 weeks
Yan, S., Yin, L
Kotecha believes in treating the whole person not just symptoms and designs personalized protocols that fit her patients real lives
My energy levels increased, I felt sharper mentally, and my sleep improved
Cost is the main drawback to liquid supplements
AT: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing original draft, Writing review & editing